Buy or sell Genapsys stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Genapsys Stock
DNA Sequencing Technology
About Genapsys Stock
GenapSys is a sequencing technology company that aims to help support the control and limit the spread of current and future outbreaks. The company's main goal is to transform research and diagnostics with an affordable, scalable genomic sequencing ecosystem.
In July 2022, Genapsys filed for Chapter 11 bankruptcy.
GenapSys was founded in 2010 and is headquartered in Redwood City, California. Notable investors include Decheng Capital, Oxford Finance Corporation, and Farallon Capital Management.
Investors
Casdin Capital
23andMe, Genapsys, ORIC Pharmaceuticals, Codiak Biosciences, Vineti, Komodo Health
Decheng Capital
Foresite Capital
EverlyWell, Crossover Health, Aetion, Genapsys, Mindstrong, DNAnexus
Oxford Finance Corporation
Plug and Play
ApplyBoard, BigID, Caresyntax, Genapsys, Albert, Beyond Pricing
Funding History
| March 2013 | $8.5M |
|---|---|
| November 2013 | $36.5M |
| December 2017 | $86.2M |
| February 2021 | $70.6M |
Management
Chief Executive Officer
Jason Myers
Chief Financial Officer
Britton Russell
Press
biospace - Sep, 9 2021
biospace - Aug, 5 2021
prnewswire - May, 27 2021
zpr - Feb, 4 2021
genomeweb - Jan, 26 2021
geekwire - Jan, 5 2021
Business Wire - Dec, 23 2020
nanalyze - Nov, 15 2020
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
